Clinical Trial Update: Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies [NA]

View source ↗

Summary

This clinical trial update explores pathological alpha-synuclein as a diagnostic biomarker for dementia with Lewy bodies, with the study status reported as not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia with Lewy Bodies

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Dementia With Lewy Bodies (DLB), Alzheimer's Disease (AD) | NA | Status: NOT_YET_RECRUITING